JM Financial has reaffirmed its bullish stance on Metropolis Healthcare, maintaining a 'Buy' rating with a target price of Rs 734. This valuation suggests a potential rally of over 27% from current trading levels, positioning the diagnostic giant as a frontrunner for investors.
According to the brokerage report, Metropolis currently stands out as the most affordably priced stock among India's major listed diagnostic providers. Analysts pointed to the firm's strategic network expansion and a robust pivot toward B2C operations as fundamental catalysts for long-term growth.
Beyond structural improvements, the firm’s bottom line is expected to strengthen as operational margins expand. By streamlining services and focusing on higher-margin consumer segments, Metropolis is well-positioned to outperform its peers in a competitive healthcare landscape.
Investors looking for exposure to the Indian healthcare services market may find this valuation discrepancy particularly attractive. As the company continues to scale its diagnostic footprint, JM Financial remains optimistic about the firm's capacity to deliver sustainable value to shareholders.
